Gilgamesh Pharmaceuticals, Inc. — Form D
Gilgamesh Pharmaceuticals, Inc. of New York, NY, a company, filed a Form D exempt-offering notice with the SEC on 2022-05-19. The offering totals $50.0M, of which $13.8M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2022-05-19
- Form: D
- Accession: 0001817048-22-000002
- Industry: Pharmaceuticals
- Exemptions: 06c
- Total offering: $50.0M
- Amount sold: $13.8M
- Remaining: $36.2M
- Minimum investment: $50K
- Investors: 14
- Date of first sale: 2022-05-16
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-446192
Issuer
- Name: Gilgamesh Pharmaceuticals, Inc.
- CIK: 0001817048
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2019
- Address: 113 University Place, New York, NY, 10003
- Phone: 3479676831
Officers, directors & promoters (17)
| Name | Role | Location |
|---|
| Robert Berman | Director | New York, NY |
| Gaetano Kevin Crupi | Director | New York, NY |
| Andrew Kruegel | Director | New York, NY |
| Amy Kruse | Director | New York, NY |
| Phil Skolnick | Director | New York, NY |
| Jonathan Sporn | Director | New York, NY |
| Yoni Falkson | Executive Officer | New York, NY |
| Laszlo Kiss | Executive Officer | New York, NY |
| Andrew Kruegel | Executive Officer | New York, NY |
| Gerard Marek | Executive Officer | New York, NY |
| Thomas Kevin Murphy | Executive Officer | New York, NY |
| Jonathan Sporn | Executive Officer | New York, NY |
| Dalibor Sames | Director | New York, NY |
| Jonathan Sporn, M.D. | Director | New York, NY |
| Jonathan Sporn, M.D. | Executive Officer | New York, NY |
| Andrew Kruegel, Ph.D. | Executive Officer | New York, NY |
| Thomas Kevin Murphy, Ph.D. | Executive Officer | New York, NY |
Other filings by this issuer (6)
More